



September 3, 2020

**Subject: Introducing the new 3000 IU vial size of ADYNOVATE® in Canada**

Dear Healthcare Professional,

Takeda Canada is pleased to announce that ADYNOVATE® is now available as a single-use vial of 3000 international units (IU) lyophilized powder for solution for 5mL intravenous injection in addition to the other already available vial sizes of 250, 500, 1000, and 2000 IUs.<sup>1</sup>

ADYNOVATE® [Antihemophilic Factor (Recombinant), PEGylated] is an extended half-life (EHL) recombinant Factor VIII (FVIII) treatment for hemophilia A, that is available through Canadian Blood Services (CBS).

ADYNOVATE®, Antihemophilic Factor [Recombinant], PEGylated, is a pegylated recombinant Antihemophilic factor (ADVATE) and is indicated in patients with hemophilia A (congenital factor VIII deficiency) for:<sup>1</sup>

- Control and prevention of bleeding episodes
- Prophylaxis to prevent or reduce the frequency of bleeding episodes
- Perioperative management

**Obtain additional information on ADYNOVATE® by:**

Consulting the Adynovate Product Monograph that is available on Takeda's website (<http://www.shirecanada.com/pm/en/Adynovate.pdf>) or by contacting Takeda Medical Information at +1-800-268-2772 or [medinfoCA@takeda.com](mailto:medinfoCA@takeda.com).

Sincerely,

Jefferson Tea, PhD, MBA  
Vice President/Head of Medical & Scientific Affairs  
Takeda Canada Inc.

Reference: 1. Adynovate Product Monograph, Shire Pharma Canada ULC (now part of Takeda) May 1, 2020

Takeda Canada Inc.  
Bay Adelaide Centre  
22 Adelaide Street West, Suite 3800  
Toronto, ON M5H 4E3, Canada  
Telephone: +1.647.798.2200 or 1.866.397.4473  
<https://www.takeda.com/en-ca>

VV-MEDMAT-22837